The BACE2-induced increase in secretion of sVEGFR3 was blocked by verubecestat, which was clinically tested for the treatment of AD and inhibits BACE2 and BACE1 (16, 19) (Supplemental Figure 2). This evidence concerns the gene BACE2 and Alzheimer disease.